Danazol 100 mg and 200 mg caps: Discontinuation
Mylan have advised that they are discontinuing their brand of danazol. Danazol will be delisted from the Schedule on 1 April 2021.
Mylan is discontinuing this product because of global supply constraints and viability of this product.
Danazol is used to treat a range of conditions, including hereditary and acquired angioedema. PHARMAC has received clinical advice that stanozolol may be a suitable alternative for angioedema. This product is not funded on the Schedule.
Prescribers will need to apply for a Named Patient Pharmaceutical Assessment (NPPA) for patients to access funded stanozolol. If you have a patient with hereditary or acquired angioedema who has previously been prescribed danazol, contact NPPA@pharmac.govt.nz
We ask that prescribers:
- do not start any new patients on danazol
- transition any patients currently prescribed danazol to an alternative treatment.
PHARMAC continues to explore options for alternative treatments.
Who to contact
If you have questions about: